US biotech Halozyme Therapeutics has entered into a definitive agreement to acquire Elektrofi, a biopharma with a breakthrough ultra-high concentration microparticle technology for biologics, branded ...

The USA’s Pfizer has struck a deal with the Trump administration to lower its US medicine prices and invest an additional $70 billion in onshore manufacturing in exchange for shelter from tariffs.

US telehealth firm LifeMD (Nasdaq: LFMD) has expanded its partnership with Danish pharma major Novo Nordisk (NOV: N) to offer Ozempic (semaglutide) for $499 a month through its platform. The move ...

US biotech Sutro Biopharma (Nasdaq: STRO) is laying off around one third of its workforce as part of another restructuring move, with the aim of extending cash resources and concentrating efforts on ...

National Respiratory Syncytial Virus (RSV) Awareness Month is observed each October in the USA, to align with the start of RSV season. The campaign highlights the global health and economic burden of ...

France's biggest drugmaker Sanofi (Euronext: SAN) has spent the last five years remaking itself. Once anchored in diabetes and cardiovascular drugs, the group now leans heavily on its vaccines unit ...

Shares of Barinthus Biotherapeutics closed down 15.5% at $1.25 yesterday on news of a merger with fellow UK-based Clywedog Therapeutics, a private company advancing novel breakthrough medicines in ...

The US Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 ...

Anglo-Dutch precision oncology company Tessellate Bio—a firm focused on developing novel synthetic lethality approaches—has announced the appointment of Katie Chapman as chief scientific officer (CSO) ...

Convatec, a UK medical products and technologies developer, today announces plans to invest more than $1 billion over the next decade to accelerate its research and development (R&D) ambitions ...

The Centers for Medicare & Medicaid Services (CMS) has finalized guidance for the third cycle of the Medicare Drug Price Negotiation Program, which will set maximum fair prices in 2028 and outline how ...

US pharma major Merck & Co (NYSE: MRK) has unveiled positive Phase III data showing its pulmonary arterial hypertension drug Winrevair (sotatercept-csrk) cut the risk of clinical worsening by 76% ...